Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:53 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,419 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Terminated Phase 3 Interventional Results available

Effectiveness of Zonisamide in Alcohol Dependent Veterans

NCT02368431
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

NCT01519531
View directory record Official record
Conditions
Drug Safety
Interventions
Placebo, VIA-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 3, 2026, 6:53 AM EST
Terminated Early Phase 1 Interventional

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

NCT04968951
View directory record Official record
Conditions
Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions
Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation
Drug · Biological
Lead sponsor
Ari M Grinspan
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Nov 3, 2026, 6:53 AM EST
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Nov 3, 2026, 6:53 AM EST
Active, not recruiting Phase 2 Interventional

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

NCT04925544
View directory record Official record
Conditions
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
Interventions
VK-2019
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

MitoQ and Exercise Effects on Vascular Health

NCT05686967
View directory record Official record
Conditions
Aging, Menopause
Interventions
MitoQ, Placebo, Aerobic exercise
Dietary Supplement · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 120 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 3, 2026, 6:53 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes

NCT07388264
View directory record Official record
Conditions
Gastrointestinal Symptoms, Constipation, Gut Health, Gastrointestinal Function
Interventions
Weizmannia (Bacillus) coagulans JBI-YZ6.3, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Nov 3, 2026, 6:53 AM EST
Terminated Phase 1 Interventional Results available

Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

NCT02630251
View directory record Official record
Conditions
Cancer, Neoplasms
Interventions
GSK2820151
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 3 Interventional Results available

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

NCT01126437
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
17,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
303
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Nov 3, 2026, 6:53 AM EST
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Risedronate for Bone Health

NCT03411902
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss, Weight Loss
Interventions
Risedronate Sodium 150 MG, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

NCT06853665
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder
Interventions
Adderall XR (mixed salts amphetamine), Placebo
Drug
Lead sponsor
Gagan Joshi
Other
Eligibility
8 Years to 18 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Nov 3, 2026, 6:53 AM EST
Not listed Phase 1Phase 2 Interventional

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

NCT01739634
View directory record Official record
Conditions
Diarrhea, Medullary Thyroid Cancer
Interventions
CASAD
Drug
Lead sponsor
Salient Pharmaceuticals Incorporated
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Nov 3, 2026, 6:53 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

4-aminopyridine for Skin Wound Healing

NCT06333171
View directory record Official record
Conditions
Wounds, Wound of Skin, Wound Heal, Wounds and Injuries
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Nov 3, 2026, 6:53 AM EST
Recruiting Phase 2Phase 3 Interventional

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

NCT07118839
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
West Haven, Connecticut • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 2 Interventional

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT05686239
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions
RL-007 (Inidascamine), Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Culver City, California • Garden Grove, California • Lafayette, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

NCT00212381
View directory record Official record
Conditions
Cervical Dysplasia
Interventions
di indolylmethane (DIM), Red rice bran
Drug · Dietary Supplement
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Nov 3, 2026, 6:53 AM EST
Completed Phase 2 Interventional Results available

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377
View directory record Official record
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Nov 3, 2026, 6:53 AM EST